Key Takeaways
- • Alafi Capital disclosed a 17.1% stake in CalciMedica, Inc. through a Schedule 13D filing on July 10, 2026, marking a shift from prior Schedule 13G filings and signaling increased investment activity in the clinical-stage biotech company.
- • The investment was built through multiple tranches: a January 2024 private placement, open-market purchases in 2024 and 2025, and a June 2026 private placement adding 3,529,192 shares at $0.8033 per unit, with additional Series A and Series B warrants pending stockholder approval.
- • CalciMedica imposed beneficial ownership blockers limiting warrant exercise to a 19.99% cap, with the 2024 warrant subject to a 4.99% blocker, restricting Alafi Capital's upside while protecting the company from unwanted control shifts.
- • The June 2026 private placement, which raised approximately $15 million (based on the unit price and share count), targeted advancement of CalciMedica's pulmonary hypertension strategy built on CRAC channel inhibition technology.
- • Alafi Capital, a healthcare and life sciences venture investor based in Emeryville, California and managed by Christopher D. Alafi, typically takes meaningful minority positions in clinical and preclinical-stage companies, consistent with its CalciMedica involvement.
Summary
Alafi Capital Company LLC has disclosed a significant 17.1% ownership stake in CalciMedica, Inc., filing a Schedule 13D with the Securities and Exchange Commission on July 10, 2026. The filing represents a material step-up in disclosure requirements from Alafi's prior Schedule 13G filings in 2025, reflecting the accumulation and nature of the investment position.
The stake was built through a deliberate, multi-year investment strategy. Alafi Capital initiated its position through a January 2024 private placement, followed by open-market purchases throughout 2024 and 2025. Most recently, the firm participated in CalciMedica's June 2026 private placement, acquiring 3,529,192 shares at $0.8033 per unit. The investment also includes warrants with exercise prices of $0.8033 (Series A) and $1.00 (Series B), though these are subject to stockholder approval and ownership limitations.
CalciMedica has structured protective provisions limiting Alafi Capital's potential control. The 2024 warrant carries a 4.99% beneficial ownership blocker, while the June 2026 warrants contain a 19.99% ownership cap, preventing Alafi from exercising them if doing so would breach that threshold. Additionally, CalciMedica agreed to register resales of shares tied to these securities, providing liquidity provisions for the investor.
Alafi Capital is a venture capital firm headquartered in Emeryville, California, and is managed by Christopher D. Alafi. The firm specializes in healthcare and life sciences investments, particularly targeting companies at clinical and preclinical development stages. Alafi typically structures its investments as meaningful minority positions while providing strategic support through key development milestones—a posture consistent with its CalciMedica involvement.
The June 2026 private placement, in which Alafi participated, was designed to support CalciMedica's focused pulmonary hypertension strategy centered on CRAC channel inhibition technology. The capital raise underscores investor confidence in the company's clinical development pipeline, despite broader biotech market pressures reflected in the company's stock performance.
The stake was built through a deliberate, multi-year investment strategy. Alafi Capital initiated its position through a January 2024 private placement, followed by open-market purchases throughout 2024 and 2025. Most recently, the firm participated in CalciMedica's June 2026 private placement, acquiring 3,529,192 shares at $0.8033 per unit. The investment also includes warrants with exercise prices of $0.8033 (Series A) and $1.00 (Series B), though these are subject to stockholder approval and ownership limitations.
CalciMedica has structured protective provisions limiting Alafi Capital's potential control. The 2024 warrant carries a 4.99% beneficial ownership blocker, while the June 2026 warrants contain a 19.99% ownership cap, preventing Alafi from exercising them if doing so would breach that threshold. Additionally, CalciMedica agreed to register resales of shares tied to these securities, providing liquidity provisions for the investor.
Alafi Capital is a venture capital firm headquartered in Emeryville, California, and is managed by Christopher D. Alafi. The firm specializes in healthcare and life sciences investments, particularly targeting companies at clinical and preclinical development stages. Alafi typically structures its investments as meaningful minority positions while providing strategic support through key development milestones—a posture consistent with its CalciMedica involvement.
The June 2026 private placement, in which Alafi participated, was designed to support CalciMedica's focused pulmonary hypertension strategy centered on CRAC channel inhibition technology. The capital raise underscores investor confidence in the company's clinical development pipeline, despite broader biotech market pressures reflected in the company's stock performance.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.